Clare Market Investments LLC Has $2.43 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Clare Market Investments LLC grew its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 45.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,750 shares of the company's stock after buying an additional 2,750 shares during the period. Cencora makes up 0.6% of Clare Market Investments LLC's portfolio, making the stock its 28th biggest position. Clare Market Investments LLC's holdings in Cencora were worth $2,433,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. JFS Wealth Advisors LLC lifted its holdings in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after acquiring an additional 46 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of Cencora during the fourth quarter worth about $29,000. SBI Securities Co. Ltd. bought a new position in shares of Cencora during the 4th quarter valued at about $30,000. Kentucky Trust Co acquired a new position in shares of Cencora in the fourth quarter valued at approximately $33,000. Finally, WASHINGTON TRUST Co increased its holdings in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cencora

In related news, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now directly owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the sale, the executive vice president now owns 14,665 shares in the company, valued at $3,934,326.20. This represents a 21.96% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,253 shares of company stock worth $11,102,417. Company insiders own 10.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on COR shares. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Bank of America boosted their price target on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. UBS Group increased their price objective on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday, April 15th. Finally, Robert W. Baird increased their price target on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $306.91.

Cencora Stock Performance

Shares of NYSE COR traded up $0.60 during mid-day trading on Friday, reaching $289.01. 1,302,615 shares of the company were exchanged, compared to its average volume of 1,529,612. The company's 50-day simple moving average is $286.06 and its 200-day simple moving average is $259.82. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a market capitalization of $56.02 billion, a P/E ratio of 41.11, a P/E/G ratio of 1.31 and a beta of 0.58. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. The business had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $3.80 EPS. As a group, research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio (DPR) is 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.